American Regent Inc (Shirley, NY) recently received FDA approval for 2 new indications for Venofer. The product was initially approved for use in the treatment of iron deficiency anemia in hemodialysis (HD) patients receiving an erythropoietin. Venofer now also is indicated for the treatment of iron deficiency anemia in peritoneal dialysis (PD) patients receiving an erythropoietin and in nondialysis chronic kidney disease (CKD) patients receiving or not receiving an erythropoietin. The product can be administered via an intravenous push (100-mg [HD] and 200-mg [CKD] doses) or by infusion (300- and 400-mg doses [PD]) depending on the indication. Venofer is available in 100-mg/5-mL single-dose vials. For more information, visit www.venofer.com, or call 800-645-1706.
Although the annual HIV diagnosis rate between 2010 and 2014 decreased for black individuals by 16.2%, blacks remain disproportionately affected by HIV/AIDS.
Clinical features with downloadable PDFs